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Abstract: Regenerative cell based therapy has potential to become effective adjuvant treatment for patients with athero-
sclerotic disease. Although data from animal studies support this notion, clinical studies undertaken in patients with acute 
and chronic coronary artery disease do not conclusively demonstrate benefits of such therapy. There are many questions 
on the stem cell translational roadmap. The basic mechanisms of stem cell-dependent tissue regeneration are not well  
understood. There is a debate regarding characterization of specific cell types conferring therapeutic effects. In particular, 
the role of endothelial progenitor cells as a specific reparative cell subtype is questioned, and the role of myeloid cell  
linage  in  fostering  of  vasculo-  and  angiogenesis  is  being  increasingly  appreciated.  Intense  discussions  surround  the  
place  of  stem/progenitor  cells  in  atherosclerosis  progression,  plaque  destabilization  and  vessel  remodeling.  This  
paper summarizes the current knowledge on the regenerative stem/progenitor cell definitions, mechanisms of stem cell 
trafficking, homing and their involvement in atherosclerosis progression. 
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INTRODUCTION 
  Atherosclerotic heart disease remains one of the  major 
causes of morbidity and mortality worldwide. Although pro-
gress  with  heart  revascularization  techniques  is  enormous, 
many patients, particularly, those with microcirculatory dis-
ease, are not good candidates for coronary angioplasty and 
bypass  graft  surgery  [1].  Post-angioplasty  restenosis  and 
graft disease substantially limit long-term benefits of heart 
revascularization  procedures  [2].  Stem/progenitor  cells, 
characterized by capacity for self-renewal and differentiation 
into different cell types, bear potential for organ regeneration 
in  various  pathological  states  [3].  Application  of  stem  
cell-based  treatment  in  clinical  cardiology  could  improve 
standards of care for many patients. 
  In 1997, Asahara et al. have reported that bone marrow 
derived  cells,  presumably,  stem/progenitor  cells,  harvested 
from peripheral blood and expanded in vitro, are able to en-
hance  neovascularization  of  ischemic  tissues  in  mice  [4]. 
Since then, various cells transplantation regiments have been 
evaluated in studies using different animal models of tissue 
ischemia and vascular injury [5-7]. Overall, preclinical work 
had generated the body of supportive data [3]. However, the 
results of clinical studies undertaken in patients with acute 
myocardial infarction and in chronic post-infarction phase of 
disease do not conclusively demonstrate benefits of cell ther-
apy [8]. The reasons for this are not clear. It is difficult to 
compare  individual  studies  as  they  differ  in  methodology 
(cell  sources  and  dosages,  routes  and  time  points  of  cell  
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measures). However, results of chronic post-infraction stud-
ies are less supportive for stem cell therapy then acute myo-
cardial infarction studies. Compared to chronic disease, sev-
eral trials in acute phase of myocardial infarction found that 
cell treatment significantly improved left ventricular function 
[9]. The effect, however, was transient. So far only one study 
reported improved left ventricular contractility at one year 
after cell therapy [10]. 
  Many questions on the stem  cell translational roadmap 
remain to be answered. The basic mechanisms of stem cell-
dependent tissue regeneration, including details of stem cell 
trafficking  and  tissue  engraftment  are  not  well  understood 
[11]. It is not clear whether effects of endogenous mobilized 
stem cells and exogenously administered cells are different. 
Furthermore, despite all efforts, the specific cell types con-
ferring therapeutic effects have not been yet defined. Intense 
debate is focused on definition of specific markers of endo-
thelial and other vascular progenitor cells [12, 13]. The role 
of myeloid cell linage in fostering of vasculo- and arterio-
genesis is increasingly appreciated [14-16].  
  Experimental studies have shown that transplanted stem 
cells gave rise to smooth muscle cells of neointima and me-
dia of recipient animal vessels [17, 18]. Plaque neovasculari-
zation, induced by pro-angiogenic stem cells contributes to 
plaque growth and, in some cases, instability [19]. Autopsy 
studies in humans have revealed presence of stem/progenitor 
cells in both stable and unstable atherosclerotic plaques [20]. 
Therefore, stem/progenitor cells could not only play a role in 
tissue revascularization, but also participate in atherosclero-
sis progression, plaque destabilization and vessel remodeling 
[21] (Fig. 1). In the context of therapeutic application, there 
is a pressing need to define factors which govern stem cells 
involvement into atherosclerosis and factors, which regulate 
stem cell-dependent tissue reparation. Unfortunately, there is 
still a lack of appropriate study models to investigate func-98    The Open Cardiovascular Medicine Journal, 2010, Volume 4  Olena Dotsenko 
tional  effects  of  stem  cells  in  pathological  conditions  in  
humans, including chronic and acute atherosclerotic disease 
and chronic heart failure.  
  Cardiovascular risk factors [22], type of tissue injury [23-
25] and the use of medications [26] – all these may have an 
impact on both stem  cell functional status  and abilities of 
affected tissues to host reparative cells. Chronic inflamma-
tion and oxidative stress could switch stem/progenitor cell-
guided  regenerative  pathway  into  pro-inflammatory  and 
proatherogenic direction, resulting in monocyte and immune 
cells recruitment to vascular wall where they maturate into 
neointima smooth muscle cells [27]. Cardiovascular medica-
tions, such as statins, angiotensin II type I receptor blockers 
and PPAR-gamma agonists, exhibit favorable effects on hu-
man stem cells cultured in vitro, increasing their survival and 
ability to regenerate ischemic tissues in animal models [26]. 
It is not clear, whether these medications modulate stem cell 
effects on atheroma growth and plaque destabilization, how-
ever studies suggest favorable effect of angiotensin II type 1 
receptor blockers [28].  
  Here we review the major outstanding questions on the 
stem cells translational roadmap in cardiovascular regenera-
tion, including controversies in stem cell definitions, mecha-
nisms of stem cell trafficking and homing and stem cell role 
in atherosclerosis progression.  
DEFINITIONS  OF  ENDOGENOUS  STEM/ 
PROGENITOR CELLS  
  Stem and progenitor cells are immature cells with high 
self-renewal potential and ability to differentiate into various 
cell types [1, 8]. Definition of stem/progenitor cells relies on 
three categories of methodological assessments: 1) prolifera-
tion, self-renewal and differentiation in culture, 2) expres-
sion of various molecular markers, 3) ability to execute spe-
cialized cell effects,  eg,  to restore  the function of damage 
tissue/organ  after  transplantation  [29].  The  sine  qua  non  
criteria of regenerative efficacy of stem/progenitor cells in 
humans are their good performance in animal transplantation 
assay [29]. However, the results obtained in animal models 
are not always transferable to humans. In order to overcome 
this shortage several groups have introduced the conception 
of humanized mice, in which various kinds of human cells 
and tissues are engrafted into experimental mice models to 
reconstitute  human  immune  system  and  other  functions  in 
the model [30].  
  The prototypes of human stem cells are embryonic stem 
cells – pluripotent cells able to differentiate into all cell types 
of adult organism. Due to allogeneic nature of cell transplan-
tation,  possibility  of  tumorogenesis  and  ethical  issues  em-
bryonic stem cells are not widely used for therapeutic pur-
poses, however, the first human trial using embryonic stem 
cells as a medical treatment has been approved recently by 
US Food and Drug Administration [31]. Recent reports have 
described reprogramming of adult differentiated cells, such 
as  fibroblasts,  into  a  state  of  pluripotency  [32].  These  in-
duced pluripotent stem cells (iPSC) are promising candidates 
for ischemic tissue regeneration as a potential new source of 
“embryonic-like” stem cells that overcome the current limi-
tations of embryonic stem cells. However, more robust data 
are  warranted  about  iPSC  trans-differentiation  into  cardio-
myocytes, vascular smooth muscle and endothelial cells in 
vivo.  
  Multipotent stem cells are usually responsible for postna-
tal tissue reparations during physiological turnover, aging or 
injury [32]. Hematopoietic and mesenchymal stem cells are 














Fig. (1). Schematic presentation of progenitor cells involvement in vessels regeneration and atherosclerosis progression.  
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regeneration.  Hematopoietic  stem  cells  have  been  isolated 
from bone marrow, peripheral blood and from umbilical cord 
blood as CD34+ and CD133+ cells, forming several types of 
well  characterized  colonies  in  culture  (erythroid,  myeloid, 
granulocyte-macrophage,  etc)  [33].  Numerous  studies  of 
bone marrow transplantation in hematological malignancies 
in humans have shown donor stem cell repopulation of re-
cipient’s  bone  marrow  and  restoration  of  haematopoietic 
function [34].  
  Mesenchymal  stem  cells  reside  predominantly  in  bone 
marrow stroma [35]. Their main function is maintenance of 
marrow mesenchymal stromal cell pool in stromal niche to 
support quiescent hematopoietic stem cells [35]. Mesenchy-
mal stem cells could also differentiate into adipocytes, os-
teoblasts,  chondrocytes  and  myoblasts.  These  cells  do  not 
express  traditional  hematopoietic  and  leukocytic  markers 
CD34, CD133, CD45 and HLA-DR, but could be character-
ized by expression of CD105, CD73 and CD90 and ability to 
adhere  to plastic (in culture) and bind variety of adhesion 
molecules [35, 36]. Due to their non-immunogenic nature, 
mesenchymal stem  cells could be used for allogenous cell 
therapy [36]. Recent work has described their adjuvant role 
in  supporting  vasculogenesis  via  secretion  of  angiogenic 
factors and recruitment of reparative stem cells to the site of 
injury [37]. Their ability for cardiogenic differentiation has 
also been reported [38]. Clinical studies on the use of mes-
enchymal stem cells for cardiac regeneration after myocar-
dial infarction are underway [37]. Stem cells, harvested from 
adipose  tissue,  have  been  also  found  to  express  adhesion 
molecules and hence to have potential to facilitate reparative 
stem cells tissue engraftment [39]. Experimental data indi-
cate that adipose derived stem cells ameliorate tissue ische-
mia, increase  tissue capillary density and differentiate into 
capillary structures in vitro [39].  
  Smooth muscle progenitor cells have been described as 
bone  marrow  resident  and  circulating  cells  that  express 
markers  of  mesenchymal/smooth  muscle  lineage,  such  as 
endoglin (CD105), calponin and a-smooth muscle  albumin 
(a-SMA) [40]. There are some controversies in phenotypic 
definition of smooth muscle progenitor cells. Smooth muscle 
cells are a highly heterogeneous cell population with differ-
ent characteristics and markers and hence their predecessors 
may  have  distinct  phenotypes  in  physiological  and  patho-
logical conditions [41].  
  It is clear now that both endothelial and smooth muscle 
cells could originate from the same paternal cells, such as 
common vascular progenitor cells. Indeed, peripheral blood 
myeloid subset of CD14+CD105+ cells have been shown to 
be able to differentiate in  culture  into endothelial-like  and 
smooth muscle cell-like lineage depending on culture condi-
tions [14]. In enhanced green fluorescence protein (EGFP) 
transgenic  mice  model,  EGFP  labeled  cells,  injected  after 
femoral artery wire injury, have been found in both neoin-
tima  and media of injured artery [42].  These  cells stained 
positively  for  both  endothelial  marker  CD31  and  a-SMA, 
implying the presence of a cohort of cells able to maturate in 
vivo into both endothelial and smooth muscle cells [42].  
  Much discussed is the question how endogenous smooth 
muscle progenitor cells regulate atherosclerosis progression 
[21, 41]. Animal studies with progenitor cell transplantation 
provided ambiguous data. Studies have shown that smooth 
muscle progenitor cells are present in atherosclerotic plaque 
caps, neointima, media and adventitia of injured vessels [21]. 
Local inhibition of smooth muscle progenitor cells adhesion 
after arterial injury was reported to attenuate neointimal pro-
gression [42]. At the same time, recruitment of smooth mus-
cle progenitor cells in chronic advanced atherosclerosis was 
shown to aid in stable plaque maintenance [43].  
  Skeletal  myoblasts  and  resident  cardiac  stem  cells  are 
considered as capable to differentiate into mature cardiocytes 
[44, 45]. However, clinical studies with myoblast injections 
into  cardiac  muscle  have  shown  increased  risk  of  cardiac 
arrhythmias [44]. Intense research is conducted on isolation, 
expansion and differentiation of resident cardiac stem cells 
[45]. Recent study has reported isolation of c-kit+  cardiac 
stem cells from human right atrium [46]. The major obstacle 
in the laboratory expansion of resident cardiac stem cells is 
the  need  for  cardiac  biopsy  in  order  to  harvest  the  cells. 
However, for high risk patients undergoing cardiac surgery, 
harvesting c-kit+ cells from right atrium could be justifiable, 
if adequate expansion protocol is developed and their trans-
plantation efficacy is proven.  
CONTROVERSIES  IN  CHARACTERIZATION  
OF  ENDOTHELIAL  PROGENITOR  CELLS  AND 
EMERGING ROLE OF MYELOID PROGENITORS IN 
CARDIOVASCULAR REGENERATION 
  There  is no consensus yet regarding definitions of dis-
tinct  cell  types  committed  to  postnatal  angiogenesis  and 
ischemic tissue regeneration. One of the most controversial 
topics is phenotypic and functional characterizations of en-
dothelial progenitor cells. 
  Hematopoietic and non-hematopoietic vasculogenic pro-
genitor cells are originating from common embryonic prede-
cessor hemangioblast [47]. Hence, Asahara et al. suggested 
that circulating bone marrow-derived hematopoietic CD34+ 
cell population could contain subset of cells, maturating into 
endothelial cells and assisting in postnatal vasculogenesis [4, 
48]. Subsequent studies have adopted the term “endothelial 
progenitor cells” and applied it to circulating and bone mar-
row  resident  cells,  co-expressing  hematopoietic  (CD34, 
CD133) and endothelial markers, such as VEGF receptor-2 
(VEGFR2), CD31, Tie-2, vascular endothelial (VE) cadherin 
and endothelial nitric oxide synthase (eNOS) [12, 49, 50]. 
Numerous animal studies have shown ability of circulating 
and marrow-derived cells to enhance ischemic tissue revas-
cularization. However, most of the studies have transplanted 
non-selective bone marrow cell populations rather then cell 
subsets,  co-expressing  hematopoietic  and  endothelial  anti-
gens,  forming  endothelial-like  colonies  in  culture.  Recent 
study, however, have demonstrated improvement of cardiac 
function  after  intracoronary  injection  of  CD34+chemokine 
receptor 4 (CXCR4)+ cells in humans [51]. 
  Unfortunately, mentioned phenotypic markers could not 
accurately discriminate endothelial progenitor cells, as vari-
ous cell types share the same antigens. For example, CD14+ 
myeloid  subsets  express  CD34  and  CD133,  as  well  as 
VEGFR2, Tie-2 and other endothelial markers [15, 16, 52]. 
Circulating mature endothelial cells are co-expressing CD34 
and  various  endothelial  antigens.  Peichev  et  al.  [53]  sug-
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CD133) protocol to separate circulating putative endothelial 
progenitor  cells.  However,  recent  work  has  demonstrated 
that triple positive CD34+CD133+VEGFR2+ cell population 
is  hematopoietic,  but  not  an  endothelial  progenitor  [54]. 
CD34+CD133+VEGFR2+  enriched  cells  formed  hema-
topoietic colonies, but not endothelial cell like structures in 
vitro [54]. Progenitor cells co-expressing hematopoietic and 
endothelial markers have not been utilized for vascular re-
generative therapy in humans and hence their transplantation 
effects are not known.  
  In addition to  surface  antigen defining  techniques,  two 
major culture-based approaches have been proposed to iden-
tify  endothelial  progenitor  cells  [49,  50,  55].  In  so  called 
early  colony  forming  unit  (CFU)  [49]  assay  mononuclear 
cells are plated on fibronectin coated plates; after few days 
of culture non-adherent cells are removed and adherent cells 
are remaining in culture for the next 5-7 days. In late out-
growth endothelial cell (OEC) assay mononuclear cells are 
let to grow for 14-21 days forming characteristic cobblestone 
colonies. Cells in early colonies are positive for both endo-
thelial and myeloid progenitor cell markers and maturate into 
macrophages  that  express  non-specific  esterase  and  ingest 
bacteria [56]. Their progeny fail to form human-like blood 
vessels when implanted into immunodeficient mice [56]. In 
contrast, cells in OEC do not express CD14 and other mye-
loid markers, they are characterized by higher proliferative 
capacity,  could  form  capillary-like  structures  in  vitro  and 
participate into vasculogenesis in mice models in vivo [57]. 
Therefore, OEC assay, most likely, is identifying vascular or, 
more  specifically,  endothelial  cell  progeny,  whereas,  early 
colony assay - monocytic/macrophage cell lineage. Indeed, 
fibronectin coated plates culture techniques are used to iso-
late  circulating  monocytes  [58].  In  addition,  circulating 
CD14+CD45+ monocytes and tissue macrophages have been 
shown to exhibit endothelial-like cell features, such as up-
take  of  acetylated  low  density  lipoprotein,  binding  ulex 
lectin and expressing of eNOS [59].  
  Clinical  studies,  exploring  association  between  cardio-
vascular risks and circulating progenitor cells, have utilized 
both  culture  techniques  to  measure  progenitor  cell  clono-
genic  potential.  Most  of  the  studies  have  reported  inverse 
relationship between circulating  endothelial progenitor cell 
number  and  severity  of  cardiovascular  disease  [12,  50]. 
Thus, it is plausible, that both early and late colony forming 
subsets of circulating progenitor cells play a role in cardio-
vascular regeneration.  
  It  was  reported,  that  CD14+  myeloid  subsets  isolated 
from peripheral blood formed morphologically identical  to 
early  endothelial  progenitor  cell  colonies  in  culture,  and, 
when injected intravenously in mice with hindlimb ischemia, 
improved muscle perfusion and increased capillary density 
[16,  52].  Subpopulation  of  monocyte-derived  CD34+/ 
CD14+, CD14+VEGFR2+CXCR2+ and Tie2+CD14+CD16+ 
cells,  releasing  angiogenic  growth  factors,  and  directly  
incorporating into neo-endothelium, has also been described 
[12]. 
  Under conditions of vascular ischemia mobilized subsets 
of hematopoietic progenitor cells could undergo “alternative 
activation  pathway”,  maturating  into  non-inflammatory 
macrophages and dendritic cells, able to migrate through the 
endothelial barrier into the matrix of the tissue [12]. These 
migrated cells have been shown to foster local production of 
innate immune cells and to release chemotactic and growth 
factors stimulating recruitment of circulating and tissue resi-
dent progenitor cells to the site of injury aiming to preserve 
homeostasis  of  healthy  vessels  [60].  Ex  vivo  activation  of 
monocytes chemoattractant protein-1 stimulates adhesion of 
bone marrow-derived monocyte-like cells to injured arteries, 
resulting in re-endothelialization and reduction in neointima 
formation [52]. 
STEM/PROGENITOR  CELL  TRAFFICKING  AND 
HOMING 
  Regenerative  effect  of  all  non-tissue-resident  stem/ 
progenitor  cells,  including  exogenously  administered  cells, 
depends  on  their  recruitment  into  the  site  of  injury.  This 
process  is  regulated  by  molecular  signals  from  damaged  
tissue  and  schematically  could  be  presented  as  stem  cells 
mobilization,  migration  with  circulating  blood  and  tissue 
engraftment including in situ proliferation and differentiation  
[61].  
  Many details of hematopoietic cells trafficking from bone 
marrow to ischemic non-marrow tissues have been clarified 
in  experimental  animal  models.  Responding  to  the  signals 
from the periphery stem/progenitor cells migrate within bone 
marrow from the steady-state stromal niche into the vascular 
compartment  and  then  are  released  into  circulating  blood 
[61]. The most powerful signal for stem cells mobilization 
and  homing  is  chemokine  stromal  cell  derived  factor-1 
(SDF-1 also known as CXCL12), which binds to its specific 
receptor CXC4 [62].  
  In normal hematopoiesis SDF-1 plays a crucial role for 
circulating stem cell homing to bone marrow [62]. In physio-
logical  conditions  various  tissues,  including  bone  marrow 
stroma,  constitutively  express  SDF-1  [62].  In  absence  of 
injury  in  peripheral  tissues,  there  is  a  significant  gradient 
between concentration of SDF-1 in bone marrow and in pe-
ripheral tissues [62]. During hypoxia, ischemia and inflam-
mation SDF-1 is up-regulated and marrow-tissue SDF-1 gra-
dient is reversed [63-65]. Activated platelets express SDF-1 
and hence contribute to the recruitment of circulating pro-
genitor cells to the growing platelet thrombi on the site of 
arterial injury. The gene expression of SDF-1 is regulated by 
the  transcription  factor  hypoxia-inducible  factor-1  (HIF-1) 
[66].  The  expression  of  HIF-1  is  up-regulated  in  hypoxic, 
injured and ischemic tissues and recruitment of regenerative 
CXCR4+ progenitor cells is mediated by hypoxic gradients 
via HIF-1-induced expression of SDF-1 [66]. During ische-
mia  or  inflammation  VEGF,  erythropoietin,  granulocyte-
colony  stimulating  factor  (G-CSF)  and  nitric  oxide  (NO) 
exert mobilizing action on hematopoietic stem cells in part 
via SDF-1 route [62-66]. Mobilization of progenitor cells to 
the site of injury was significantly impaired in eNOS knock-
out mice [67]. SDF-1 induces the release of NO in endothe-
lial cells, creating positive feedback loops for regenerative 
cells  chemotaxis  [66-68].  Recent  reports  have  shown  in-
volvement  of  Notch  and  sphingosine-1  phosphate  system 
signaling  in  the  activation  of  CXCR4  under  conditions  of 
tissue ischemia [68]. Clinical studies have demonstrated, that 
cardiovascular  surgical  intervention  had  mobilizing  effect  
on CD34+, CD34+CXCR4+ cells and increased number of 
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  In  addition  to  SDF-1-CXCR4+  axis,  important  role  in 
stem  cells  recruitment  to  tissue  play  soluble  or  surface  
arrested angiogenic CC- and inflammatory CXC-chemokines 
(CCL2,  CXCL1,  CXCL7)  and  their  respective  receptors 
(CCR2,  CXCR2,  CXCR4)  on  stem/progenitor  cell  surface 
[68]. In particular, up-regulation of CXCR2 ligands CXCL1 
and  CXCL7  during  arterial  injury  resulted  in  selective  
recruitment of myeloid CD14+ vascular progenitor subsets 
to sites of injury, increasing of re-endothelialization [70].  
ATHEROSCLEROSIS  PROGRESSION  VERSUS  
ENDOTHELIAL  RECOVERY:  CONTRIBUTION  OF 
STEM/PROGENITOR CELLS 
  Development of atherosclerotic lesions depends on con-
tinuous focal inflammation initiated by endothelial damage, 
followed by sub-endothelial accumulation of lipids and im-
mune  cells.  Local  resident  macrophages  release  a  host  of 
pro-inflammatory  Th1-type  cytokines  (gamma  interferon, 
tumor  necrosis  factor  alpha  and  interleukin  (IL)-2),  which 
quickly recruit circulating inflammatory and immune mono-
nuclear cells to subendothelial matrix, perpetuating inflam-
matory vicious circle [60]. At the same time, as a compensa-
tory  reparation  response,  macrophages  undergo  alternative 
activation  (develop  into  M2  type  cells)  to  support  vessel 
healing  [71].  M2  cells  secrete  Th2-type  cytokines  and 
chemokines (IL-3, IL-8, G-CSF, etc), which mediate mobili-
zation of regenerative progenitor cells [71]. Upon atheroscle-
rosis  progression  critical  reduction  in  blood  flow  triggers 
compensatory angiogenesis to diminish tissue ischemia. Mo-
lecular  stimuli from  ischemic  tissues  attract bone  marrow’ 
and circulating stem/progenitor  cells. Adequate  endothelial 
regeneration  is  crucial  for  prevention  of  atheroma  growth 
[61].  Studies  on  chimeric  animals  carrying  EGFP  positive 
bone marrow cells have demonstrated that these cells con-
tribute to endothelial repair after injury [42]. Transfusion of 
healthy wild-type mice bone marrow-derived cells into athe-
rosclerotic Apolipoprotein E-knockout (ApoE
-/-) mice lead to 
improvement  in  endothelial  function  and  inhibited  athero-
sclerosis  progression  [72].  Over-expression  of  angiogenic 
CC-chemokine  L2  in  infused  bone  marrow  mononuclear 
cells significantly reduced neointima formation and acceler-
ated re-endothelialization via recruitment of CCR2+ progeni-
tor cells [52]. It is well known that inhibition of proinflam-
matory  macrophage  migration  into  atherosclerotic  lesions 
leads  to  a  more  stable  plaque  phenotype.  Recent  study  
reported  that  blockage  of  monocyte  inflammatory  factor, 
which  regulates  both  macrophage  migration  and  CXCR4  
and CXCR2 expression, resulted in reduced neointima area 
[73]. 
  However, in contrast to antiatherogenic effects, circulat-
ing and marrow-resident stem/progenitor cells participate in 
vessel remodeling and plaque angiogenesis, supporting athe-
rosclerosis  progression.  It  has  been  demonstrated,  that  in-
fused progenitor cells in ApoE
-/- mice increased plaque size 
and  converted  its  phenotype  to  unstable  one  [74].  In  vivo 
seeding of CD34+ progenitor cells to the surface of a graft 
stimulated neointimal hyperplasia [5].  
  The contribution of stem/progenitor cells to atherosclero-
sis progression has been confirmed in numerous studies util-
izing animal models of transplant atherosclerosis and bone 
marrow transplantation in conjunction with vascular injury. 
Donor-derived  smooth  muscle  cells  were  identified  within 
the  atherosclerotic  vessel  wall  in  patients  after  sex-
mismatched  bone  marrow  transplantation  [75].  It  appears 
that  cellular  constituents  of  vascular  lesions  vary  with  the 
type  of  injury  (primary  atherosclerosis,  post-angioplasty 
restenosis or intimal hyperplasia of vein graft) [76]. This has 
been studied in detail in animal bone marrow transplantation 
vascular injury model studies. It was shown that type of vas-
cular  injury  (wire  injury,  vessel  ligation,  perivascular  cuff 
induced  trauma)  determined  the  number  of  bone  marrow 
cells  migrated  to  neointima  [42].  The  largest  numbers  of 
transplanted bone marrow derived cells was found in neoin-
tima after wire injury with vessel wall dilatation and endo-
thelial denudation (injury, which share similarities with an-
gioplasty procedure in humans) [42]. Interestingly, the de-
gree of vessel injury-related inflammation (irrespective from 
the type of injury) did not intervene with the contribution of 
bone marrow derived cells to the neointima [42].  
  The source of progenitor cells conferring proatherogenic 
effects (such as neointima growth) remains a matter of de-
bate. Transplant atherosclerosis animal studies have shown 
that endothelial cells of microvessels within allograft athero-
sclerotic  vessels  are  derived  from  recipient  bone  marrow 
progenitor cells [77]. At the same time, it was shown, that 
Sca+lin- progenitor cells in allograft vessels have migrated 
from adventitia to the neointima, were they maturated into 
smooth muscle cells [78]. Furthermore, it was reported, that 
smooth muscle cells in advanced atherosclerosis have origi-
nated from the vessel wall and healing after plaque rupture 
mainly involved local, but not circulating cells [43].  
  Molecular  mechanisms  of  endogenous  progenitor  cell 
contribution to atherosclerosis are not well understood. The 
evidence is emerging about the role of SDF-1/CXCR4 and 
CXCL1/CXCR2 axes [27]. However, there are controversies 
between different studies.  
  It was suggested that SDF-1 may have plaque stabilizing 
effects [79]. It was found that smooth muscle and endothelial 
cells  in  stable  plaques  express  SDF-1  and  patients  with  
unstable coronary artery disease have reduced levels of SDF-
1  in  plasma  [80].  At  the  same  time,  it  has  been  shown,  
that blocking of SDF-1 resulted in significant reduction of 
neointima  formation  after  arterial  injury  in  ApoE
-/-  mice, 
implicating SDF-1 role in vessel remodeling [79]. Notably, 
blocking  of  SDF-1  in  the  same  study  did  not  reduce  
re-endothelialization after injury [79]. Continuous blockage 
of SDF-1 receptor CXCR4 resulted in aggravation of athero-
sclerosis  in  mice  via  increasing  homing  of  neutrophils, 
whereas, smooth muscle progenitor cells recruitment was not 
changed [81]. In contrast, recent work has shown that treat-
ment with CXCR4 antagonist decreased neointima formation 
and  smooth  muscle  cell  mobilization  after  arterial  injury, 
however had no effect on reendothelialization after endothe-
lial denudation [82].  
  Blockage of CXCR2 ligand CXCL1 inhibited endothelial 
recovery  and  increased  neointima  growth  in  ApoE
-/-  mice 
after wire injury in the carotid artery [83]. Neointima macro-
phages were identified as a major source of CXCL1 in in-
jured  vessels  in  ApoE
-/-  mice  [83].  It  is  established,  that 
CXCL1  promotes  atherogenesis  through  increased  recruit-
ment of monocytes [83]. Increased levels of CXCR2 ligands 102    The Open Cardiovascular Medicine Journal, 2010, Volume 4  Olena Dotsenko 
CXCL1  and  CXCL7  were  related  in  clinical  studies  with 
plaque destabilization and blockage of CXCR2 was associ-
ated with stable plaque phenotype [42].  
  Thus,  it  appears  that  molecular  stimuli  which  regulate 
atherosclerosis  progression  coordinate  vessel  wall  engraft-
ment of both progenitor and inflammatory cells. It is likely, 
that widespread chronic recruitment of myeloid progenitors 
could potentiate atherosclerosis progression via maintanence 
of continous inflammation and plaque neovascularization. In 
parallel, recruitment of progenitor cells giving rise to smooth 
muscle  cells  within  atherosclerotic  plaque  could  maintain 
plaque stability. In acute vessel injury, recruitment of pro-
genitor  cells  able  to  restore  endothelial  layer  may  support 
vessel recovery.  
CONCLUSIONS 
  Recent  developments  in  stem  cells  research  have  re-
vealed  new  facts  about  biology  of  endogenous  stem/ 
progenitor  cells  in  humans.  Phenotypic  and  functional  
plasticity  of  bone  marrow  resident  and  circulating  stem/ 
progenitor  cells  has  been  increasingly  appreciated.  There-
fore,  there  is  a  need  to  put  even  more  efforts  to  develop 
methodologies  able  to  identify  distinct  cell  types  prospec-
tively or to predict reparative effects of endogenous mobi-
lized  or  exogenously  administered  cells.  The  contribution  
of  stem/progenitor  cells  to  atherosclerosis  progression  and 
vascular  remodeling  after  injury  in  humans  is  established, 
however  many  details  are  still  unknown.  It  is  hoped  that  
future studies would explore ambivalent role of stem cells in 
tissue  regeneration  and  in  atherosclerosis  progression.  In  
the  respect  of  the  main  clinical  endpoint,  it  is  important  
to get selective control over specific patient-related factors 
that may have an impact on cell therapy outcome, such as 
severity  of  atherosclerosis,  cardiovascular  risk  factors  and 
co-morbid background. 
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